Adnan M. M. Mjalli,Christopher Behme,Daniel P. Christen,Devi Reddy Gohimukkula,Dharma Rao Polisetti,James C. Quada, Jr.,Jennifer L. R. Freeman,Kalpathy Santhosh,Muralidhar Bondlela,Mustafa Guzel,Ravin
申请号：
US13707265
公开号：
US08987295B2
申请日:
2012.12.06
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
